A 30-year-old woman with chronic hypertension trying to conceive

JAMA

Volumn 298, Issue 13, 2007, Pages 1548-1558

  Powrie, Raymond O ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; FLUOXETINE; MAGNESIUM;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREAST FEEDING; CASE REPORT; CHRONIC DISEASE; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; ARTIFICIAL INSEMINATION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG EFFECT; FEMALE INFERTILITY; HYPERTENSION; LACTATION; MATERNAL CARE; PATHOPHYSIOLOGY; PUERPERIUM; RISK ASSESSMENT; RISK REDUCTION;

ADULT; ANTIHYPERTENSIVE AGENTS; BREAST FEEDING; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION; INFERTILITY, FEMALE; INSEMINATION, ARTIFICIAL; LACTATION; POSTPARTUM PERIOD; PRE-ECLAMPSIA; PRECONCEPTION CARE; PREGNANCY; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 34948817643     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.13.1548     Document Type: Article

References (100)

1. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560-2571.
2. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716.
3. Pomini F, Scavo M, Ferrazzani S, De Carolis S, Caruso A, Mancuso S. There is poor agreement between manual auscultatory and automated oscillometric methods for the measurement of blood pressure in normotensive pregnant women. J Matern Fetal Med. 2001;10(6):398-403.
4. Gupta M, Shennan AH, Halligan A, Taylor DJ, de Swiet M. Accuracy of oscillometric blood pressure monitoring in pregnancy and preeclampsia. Br J Obstet Gynaecol. 1997;104(3):350-355.
5. Natarajan P, Shennan AH, Penny J, Halligan AW, de Swiet M, Anthony J. Comparison of auscultatory and oscillometric automated blood pressure monitors in the setting of preeclampsia. Am J Obstet Gynecol. 1999;181(5 pt 1):1203-1210.
6. Ostchega Y, Dillon C, Carroll M, Prineas RJ, McDowell M. US demographic trends in mid-arm circumference and recommended blood pressure cuffs: 1988-2002. J Hum Hypertens. 2005;19(11):885-891.
7. Duggan PM, Miller J. Blood pressure measurement in pregnancy - a survey of methods used in teaching hospitals in South Australia. Aust N Z J Obstet Gynaecol. 1998;38(2):197-199.
8. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665-675.
9. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep. 2003;5(6):513-520.
10. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. (4).
11. Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI. Curr Hypertens Rep. 2005;(3).
12. Campese VM. Calcium, parathyroid hormone, and blood pressure. Am J Hypertens. 1989;2(2 pt 2):34S-44S.
13. Salem MM. Pathophysiology of hypertension in renal failure. Semin Nephrol. 2002;22(1):17-26.
14. Turnbull JM. Is listening for abdominal bruits useful in the evaluation of hypertension? JAMA. 1995;274(16):1299-1301.
15. Rao PS. Coarctation of the aorta. Curr Cardiol Rep. 2005;7(6):425-434.
16. Coccagna G, Pollini A, Provini F. Cardiovascular disorders and obstructive sleep apnea syndrome. Clin Exp Hypertens. 2006;28(3-4):217-224.
17. Beilin LJ, Puddey IB. Alcohol and hypertension: an update. Hypertension. 2006;47(6):1035-1038.
18. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4)(suppl):S5-S22.
19. Lippi G, Albiero A, Montagnana M, et al. Lipid and lipoprotein profile in physiological pregnancy. Clin Lab. 2007;53(3-4):173-177.
20. Os I, Oparil S, Gerdts E, Hoieggen A. Essential hypertension in women. Blood Press. 2004;13(5):272-278.
21. Hayes SN; Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Evidence-based medicine and treatment of hypertension in women: results of trials. J Hypertens Suppl. 2002;20 (2):S47-S51.
22. Safar ME, Smulyan H. Hypertension in women. Am J Hypertens. 2004;17 (1):82-87.
23. McBride SM, Flynn FW, Ren J. Cardiovascular alteration and treatment of hypertension: do men and women differ? Endocrine. 2005;28(2):199-207.
24. Quan A, Kerlikowske K, Gueyffier F, Boissel JP; INDANA Investigators. Pharmacotherapy for hypertension in women of different races. Cochrane Database Syst Rev. 2000;(3):CD002146.
25. Stergiou GS, Salgami EV; World Health Organization-International Society of Hypertension (WHO-ISH); Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7); European Society of Hypertension-European Society of Cardiology (ESH-ESC). New European, American and international guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther. 2004;2(3):359-368.
26. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789.
27. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
28. Hale TW. Medications and Mothers' Milk. 12th ed. Amarillo, TX: Hale Publishing; 2006.
29. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 1996;27(suppl 3):S49-S54.
30. Jouppila P, Kirkinen P, Koivula A, Ylikorkala O. Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in preeclampsia. Br J Obstet Gynaecol. 1986;93(6):543-547.
31. Magee LA. Drugs in pregnancy: antihypertensives. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):827-845.
32. Bortolus R, Ricci E, Chatenoud L, Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG. 2000;107 (6):792-794.
33. Childress CH, Katz VL. Nifedipine and its indications in obstetrics and gynecology. Obstet Gynecol. 1994;83(4):616-624.
34. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;(3):CD002863.
35. Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol. 2000;88(1):15-26.
36. Reynolds B, Butters L, Evans J, Adams T, Rubin PC. First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child. 1984;59 (11):1061-1063.
37. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of the Canadian Hypertension Society Consensus Conference, 3: pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997;157(9):1245-1254.
38. Hartikainen-Sorri AL, Heikkinen JE, Koivisto M. Pharmacokinetics of clonidine during pregnancy and nursing. Obstet Gynecol. 1987;69(4):598-600.
39. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS; ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354(17):1796-1806.
40. Armario P, Hernandez del Rey R, Pardell H. Adverse effects of direct-acting vasodilators Drug Saf. 1994;11(2):80-85.
41. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984; 150(7):831-835.
42. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82(1):23-28.
43. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006;3):CD001449.
44. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;(1):CD002252.
45. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-649.
46. Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol. 1977;84(6):419-426.
47. Borghi C, Esposti DD, Cassani A, Immordino V, Bovicelli L, Ambrosioni E. The treatment of hypertension in pregnancy. J Hypertens Suppl. 2002;20(2):S52-S56.
48. Magee LA, Abdullah S. The safety of antihypertensives for treatment of pregnancy hypertension. Expert Opin Drug Saf. 2004;3(1):25-38.
49. Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev. 2007;(1):CD004451.
50. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-2451.
51. Ayala DE, Hermida RC. Influence of parity and age on ambulatory monitored blood pressure during pregnancy. Hypertension. 2001;38(3 pt 2):753-758.
52. August P, Helseth G, Cook EF, Sison C. A prediction model for superimposed preeclampsia in women with chronic hypertension during pregnancy. Am J Obstet Gynecol. 2004;191(5):1666-1672.
53. Sibai BM, Lindheimer M, Hauth J, et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. N Engl J Med. 1998;339(10):667- 671.
54. Mulrow CD, Chiquette E, Ferrer RL, et al. Management of Chronic Hypertension During Pregnancy. Rockville, MD: Agency for Healthcare Research and Quality; August 2000. Evidence Report/Technology Assessment 14. AHRQ publication 00-E011.
55. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol. 1986;155(5):1011-1016.
56. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100 (2):369-377.
57. Richardson DK. A woman with an extremely premature newborn. JAMA. 2001;286(12):1498-1505.
58. von Dadelszen P, Magee LA, Taylor EL, et al; Canadian Neonatal Network. Maternal hypertension and neonatal outcome among small for gestational age infants [published correction appears in Obstet Gynecol. 2006;107(1):209]. Obstet Gynecol. 2005;106(2):335-339.
59. Working Group Report on High Blood Pressure in Pregnancy, National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health; July 2000. NIH publication 00-3029.
60. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355(9198):87-92.
61. American College of Obstetricians and Gynecologists. Chronic Hypertension in Pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; July 2001. ACOG practice bulletin 29.
62. Papageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of preeclampsia by maternal characteristics and uterine artery Doppler. BJOG. 2005;112(6):703-709.
63. Hershkovitz R, de Swiet M, Kingdom J. Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy. 2005;24(3):273-280.
64. Farmakides G, Schulman H, Schneider E. Surveillance of the pregnant hypertensive patient with Doppler flow velocimetry. Clin Obstet Gynecol. 1992;35 (2):387-394.
65. Neilson JP, Alfirevic Z. Doppler ultrasound for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev. 2000;(2):CD000073.
66. Lim KH, Friedman SA, Ecker JL, Kao L, Kilpatrick SJ. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 1998;178(5):1067-1071.
67. Roberts JM, Bodnar LM, Lain KY, et al. Uric acid is as important as proteinuria in identifying fetal risk in womenwith gestational hypertension. Hypertension. 2005;46(6):1263-1269.
68. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-1594.
69. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet. 2005;365(9461):785-799.
70. Walker JJ. Preeclampsia. Lancet. 2000;356(9237):1260-1265.
71. Levine RJ, Lam C, Qian C, et al; CPEP Study Group. Soluble endoglin and other circulating anti-angiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005.
72. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.
73. Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community BMJ. 2005;330(7491):576-580.
74. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006;(3):CD001059.
75. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet. 2001;357(9251):209-215.
76. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Preeclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomized placebo-controlled trial. Lancet. 2006;367 (9517):1145-1154.
77. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338(11):701-705.
78. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women. Lancet. 1994;343(8898):619-629.
79. Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev. 2004;(1):CD004659.
80. Askie LM, Duley LA, Henderson-Smart DJ, et al. Anti-platelet agents for prevention of pre-eclampsia: ameta-analysis of individual patient data. Lancet. 2007; 369(9575):1791-1798.
81. Altman D, Carroli G, Duley L, et al; Magpie Trial Collaboration Group. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? the Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-1890.
82. Sciscione AC, Ivester T, Largoza M, Manley J, Shlossman P, Colmorgen GH. Acute pulmonary edema in pregnancy. Obstet Gynecol. 2003;101(3):511-515.
83. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-960.
84. Walters BN, Thompson ME, Lee A, de Swiet M. Blood pressure in the puerperium. Clin Sci (Lond). 1986;71(5):589-594.
85. Ferrazzani S, De Carolis S, Pomini F, Testa AC, Mastromarino C, Caruso A. The duration of hypertension in the puerperium of pre-eclamptic women: relationship with renal impairment and week of delivery. Am J Obstet Gynecol. 1994;171(2):506-512.
86. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246-254.
87. Magee L, Sadeghi S. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2005;(1):CD004351.
88. Roberts JM, Gammill H. Preeclampsia and cardiovascular disease in later life. Lancet. 2005;366(9490):961-962.
89. Funai EF, Friedlander Y, Paltiel O, et al. Long-term mortality after preeclampsia. Epidemiology. 2005;16(2):206-215.
90. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366(9499):1797-1803.
91. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk for ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet. 2001;357(9273):2002-2006.
92. Haukkamaa L, Salminen M, Laivuori H, et al. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol. 2004;93(6):805-808.
93. Brown DW, Dueker N, Jamieson DJ, et al. Preeclampsia and the risk of ischemic stroke among young women: results from the Stroke Prevention in Young Women Study. Stroke. 2006;37(4):1055-1059.
94. Wolf M, Hubel CA, Lam C, et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab. 2004;89(12):6239-6243.
95. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143-148.
96. Sullivan M, Elder M, de Swiet M. Too little, too late. Am J Obstet Gynecol. 1999;181(2):508-509.
97. Coomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS. Individualising use of aspirin to prevent preeclampsia: a framework for clinical decision making. BJOG. 2003;110(10):882-888.
98. Kristensen J, Vestergaard M, Wisborg K, Kesmodel U, Secher NJ. Prepregnancy weight and the risk of stillbirth and neonatal death. BJOG. 2005; 112(4):403-408.
99. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet. 2006;368(9542):1164-1170.
100. Richardson AD, Piepho RW. Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000;38(2):75-79.